This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics
May 19-22, 2025
Manchester Grand Hyatt San DiegoSan Diego, CA

Dr. Wen-Hsuan Chang, PhD
Associate VP, Discovery & Early Development at AcuraStem
Speaker

Profile

Dr. Wen-Hsuan Chang is an Associate Vice President, Discovery and Early Development, at AcuraStem. She leads the biology team on the NeuroRx® technology platform. Dr. Chang’s team has performed the detailed work to understand the therapeutic mechanisms underlying our drug programs, and utilizing that knowledge for clinical biomarker development. They are continually assessing new targets for advancement into AcuraStem’s preclinical pipeline, continually innovating the patient-specific models of the NeuroRx® technology platform to recapitulate new aspects of disease, and expanding the platform into new indications. Dr. Chang previously led the establishment and validation of the NeuroRx® platform from the biology side. She received her Ph.D. in Chemical Engineering from the University of Southern California. After her Ph.D., Dr. Chang performed postdoctoral work in the laboratory of AcuraStem’s co-founder and scientific advisory board chairman, Dr. Justin Ichida at USC, where she identified key mechanisms by which the C9orf72 repeat expansion causes neurodegeneration in ALS and frontotemporal dementia.

Agenda Sessions

  • Using the iNeuroRx® Technology Platform to Develop Disease-Modifying Treatments for ALS and FTD

    5:00pm